Xi Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xi Li has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Jian Wang
Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, No. 6 Shuangyong Road, Nanning, Guangxi 530021, China
3 shared publications Wei Zhou
Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning, Guangxi, 530021, People's Republic of China
3 shared publicationsHaiqing Zhu
Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning, Guangxi, 530021, People's Republic of China
2 shared publicationsMin Jin
Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory The First Affiliated Hospital of Guangxi Medical University Nanning China
2 shared publications- Sihui Li
Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory The First Affiliated Hospital of Guangxi Medical University Nanning China
2 shared publications - Yanting Jiang
Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Department of Clinical Laboratory The First Affiliated Hospital of Guangxi Medical University Nanning China
2 shared publications
Latest Publications
- Open Access
- 6 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (23) , e42639
Correlation study between clinical phenotypes and autoantibodies in systemic sclerosis in Southwest China
This study investigates the characteristics of baseline data and the correlation between autoantibodies and clinical phenotypes in patients with systemic sclerosis (SSc) from Southwest China. A total of 346 patients diagnosed with SSc between 2021 and 2023 were included. Clinical data and laboratory data were collected to analyze the relationship between autoantibodies and clinical phenotypes. The prevalence of hypertension and osteoporosis in female patients with SSc was significantly higher than that in male patients. Anti-Scl-70 antibody was positively correlated with Raynaud phenomenon, facial or acral swelling and interstitial lung disease. Anti-Ro52 antibody is positively correlated with pulmonary hypertension. Anti-Scl-70, anti-U1-nrNP, anti-SSA, and anti-Ro52 were associated with overlap syndrome of SSc and systemic lupus erythematosus. Anti-SSA and anti-Ro52 are associated with overlap syndrome of SSc and Sjogren syndrome. Anti-Scl-70 was found to be statistically different in platelet count (PLT), C3, C4, albumin, and C-reactive protein, as was anti-U1-nRNP in hemoglobin, immunoglobulin G, C3, total triglyceride, high-density lipoprotein and low-density lipoprotein, as was anti-SSA in hemoglobin, immunoglobulin G and erythrocyte sedimentation rate, as was anti-ro52 in white blood cell count (WBC) and IgG, and anti-CENP B in PLT. Our study showed that autoantibodies anti-Scl-70 and anti-Ro52 in SSc patients were associated with the clinical phenotypes of Raynaud phenomenon, facial or acral swelling, interstitial lung disease and pulmonary hypertension.
- 6 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (23) , e42639
Open AccessCorrelation study between clinical phenotypes and autoantibodies in systemic sclerosis in Southwest China
This study investigates the characteristics of baseline data and the correlation between autoantibodies and clinical phenotypes in patients with systemic sclerosis (SSc) from Southwest China. A total of 346 patients diagnosed with SSc between 2021 and 2023 were included. Clinical data and laboratory data were collected to analyze the relationship between autoantibodies and clinical phenotypes. The prevalence of hypertension and osteoporosis in female patients with SSc was significantly higher than that in male patients. Anti-Scl-70 antibody was positively correlated with Raynaud phenomenon, facial or acral swelling and interstitial lung disease. Anti-Ro52 antibody is positively correlated with pulmonary hypertension. Anti-Scl-70, anti-U1-nrNP, anti-SSA, and anti-Ro52 were associated with overlap syndrome of SSc and systemic lupus erythematosus. Anti-SSA and anti-Ro52 are associated with overlap syndrome of SSc and Sjogren syndrome. Anti-Scl-70 was found to be statistically different in platelet count (PLT), C3, C4, albumin, and C-reactive protein, as was anti-U1-nRNP in hemoglobin, immunoglobulin G, C3, total triglyceride, high-density lipoprotein and low-density lipoprotein, as was anti-SSA in hemoglobin, immunoglobulin G and erythrocyte sedimentation rate, as was anti-ro52 in white blood cell count (WBC) and IgG, and anti-CENP B in PLT. Our study showed that autoantibodies anti-Scl-70 and anti-Ro52 in SSc patients were associated with the clinical phenotypes of Raynaud phenomenon, facial or acral swelling, interstitial lung disease and pulmonary hypertension.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 9697-9710
Clinical Significance of Abnormal Serum LGALS3BP Expression in Patients with Idiopathic Inflammatory Myopathies
Objective: Idiopathic inflammatory myopathies (IIM) are classified into four subgroups: dermatomyositis (DM), anti-synthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and sporadic inclusion body myositis (sIBM); however, the role of LGALS3BP in IIM remains unclear. Our study aimed to explore the ability of LGALS3BP to discriminate between the IIM subtypes. The correlation between serum LGALS3BP levels, clinical features, and inflammatory markers in patients with IIM was also assessed. Methods: Based on the Gene Expression Omnibus (GEO) database, we used bioinformatics analysis to screen for overlapping extracellular protein-differentially expressed genes between any two groups of DM, ASS, IMNM, and healthy controls (HCs). This study enrolled 84 patients with IIM and 36 HCs, and participant baseline data and laboratory parameters were recorded. Serum LGALS3BP levels were measured using an enzyme-linked immunosorbent assay (ELISA). Results: Through bioinformatics analysis, LGALS3BP was selected as a potential biomarker for the identification of DM, ASS, IMNM, and HC. LGALS3BP expression decreased sequentially in the DM, ASS, IMNM, and HC groups, with significant differences among the two groups. The ELISA results were similar to those of the bioinformatics analysis; however, the difference in serum LGALS3BP expression between DM and ASS was not statistically significant. According to the receiver operating characteristic (ROC) curve analysis, using HC as the control group, the area under the curve (AUC) values of serum LGALS3BP levels for the diagnosis of IIM, DM, and ASS were > 0.8. In addition, patients with elevated serum LGALS3BP levels had a higher prevalence of interstitial lung disease (ILD). Serum LGALS3BP levels correlated with inflammatory markers. Conclusion: LGALS3BP is differentially expressed in DM, ASS, IMNM, and HC and may assist in assessing the severity of IIM-ILD.
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 9697-9710
Open AccessClinical Significance of Abnormal Serum LGALS3BP Expression in Patients with Idiopathic Inflammatory Myopathies
Objective: Idiopathic inflammatory myopathies (IIM) are classified into four subgroups: dermatomyositis (DM), anti-synthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and sporadic inclusion body myositis (sIBM); however, the role of LGALS3BP in IIM remains unclear. Our study aimed to explore the ability of LGALS3BP to discriminate between the IIM subtypes. The correlation between serum LGALS3BP levels, clinical features, and inflammatory markers in patients with IIM was also assessed. Methods: Based on the Gene Expression Omnibus (GEO) database, we used bioinformatics analysis to screen for overlapping extracellular protein-differentially expressed genes between any two groups of DM, ASS, IMNM, and healthy controls (HCs). This study enrolled 84 patients with IIM and 36 HCs, and participant baseline data and laboratory parameters were recorded. Serum LGALS3BP levels were measured using an enzyme-linked immunosorbent assay (ELISA). Results: Through bioinformatics analysis, LGALS3BP was selected as a potential biomarker for the identification of DM, ASS, IMNM, and HC. LGALS3BP expression decreased sequentially in the DM, ASS, IMNM, and HC groups, with significant differences among the two groups. The ELISA results were similar to those of the bioinformatics analysis; however, the difference in serum LGALS3BP expression between DM and ASS was not statistically significant. According to the receiver operating characteristic (ROC) curve analysis, using HC as the control group, the area under the curve (AUC) values of serum LGALS3BP levels for the diagnosis of IIM, DM, and ASS were > 0.8. In addition, patients with elevated serum LGALS3BP levels had a higher prevalence of interstitial lung disease (ILD). Serum LGALS3BP levels correlated with inflammatory markers. Conclusion: LGALS3BP is differentially expressed in DM, ASS, IMNM, and HC and may assist in assessing the severity of IIM-ILD.
- Open Access
- 12 December 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 37 (1)
Association between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population
Objective: The KRAS gene has a pathophysiological role in the development of many cancers. This study aims to investigate the relationship between KRAS polymorphisms and genetic susceptibility to breast cancer.Method: The rs712, rs12587 and rs9266 gene loci in the KRAS gene of 421 subjects (141 breast cancer patients, 141 benign breast tumours and 139 healthy controls) were analysed by the polymerase chain reaction and SNaPshot sequencing. Transcriptomic information on KRAS and corresponding clinical information was downloaded from the TCGA and GTEx databases. Differences in KRAS expression between breast cancer tissues and control tissues were analysed.Results: We found no significant association between KRAS rs712 and rs12587 locus gene polymorphisms and an increased risk of developing benign breast tumours and breast cancer (p > 0.05). The KRAS rs9266 locus mutation heterozygous model CT and dominant model CT + TT were significantly associated with an increased risk of breast cancer (both p < 0.05). In addition, the TAT haplotype was expressed at an increased frequency, and the GAC haplotype was expressed at a reduced frequency in breast cancer compared with controls (both p < 0.05). We found that KRAS was over expressed in breast cancer tumour tissues compared with the control tissues (p < 0.0001).Conclusion: The KRAS rs9266 gene polymorphism and the TAT haplotype may be associated with an increased risk of breast cancer in Chinese women. The GAC haplotype may be a protective factor against breast cancer.
- 12 December 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 37 (1)
Open AccessAssociation between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population
Objective: The KRAS gene has a pathophysiological role in the development of many cancers. This study aims to investigate the relationship between KRAS polymorphisms and genetic susceptibility to breast cancer.Method: The rs712, rs12587 and rs9266 gene loci in the KRAS gene of 421 subjects (141 breast cancer patients, 141 benign breast tumours and 139 healthy controls) were analysed by the polymerase chain reaction and SNaPshot sequencing. Transcriptomic information on KRAS and corresponding clinical information was downloaded from the TCGA and GTEx databases. Differences in KRAS expression between breast cancer tissues and control tissues were analysed.Results: We found no significant association between KRAS rs712 and rs12587 locus gene polymorphisms and an increased risk of developing benign breast tumours and breast cancer (p > 0.05). The KRAS rs9266 locus mutation heterozygous model CT and dominant model CT + TT were significantly associated with an increased risk of breast cancer (both p < 0.05). In addition, the TAT haplotype was expressed at an increased frequency, and the GAC haplotype was expressed at a reduced frequency in breast cancer compared with controls (both p < 0.05). We found that KRAS was over expressed in breast cancer tumour tissues compared with the control tissues (p < 0.0001).Conclusion: The KRAS rs9266 gene polymorphism and the TAT haplotype may be associated with an increased risk of breast cancer in Chinese women. The GAC haplotype may be a protective factor against breast cancer.
- Open Access
- 9 July 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (8) , e24597
Clinical significance of serum ferritin in patients with systemic sclerosis
Objective: The purpose of this study was to explore the clinical significance of serum ferritin (SF) in patients with systemic sclerosis (SSc).Methods: The levels of SF were measured in 115 patients with SSc and 117 healthy controls (HCs). Clinical characteristics and laboratory indexes between the high ferritin SSc group and the normal ferritin SSc group were analyzed.Results: The level of SF in SSc patients was significantly higher than that in HCs (319.78 [179, 554.33] ng/ml vs. 99 [49.03, 164.29] ng/ml, p < 0.01). Compared with the normal ferritin SSc group, the high ferritin SSc group was more likely to develop skin diffuse cutaneous SSc, fingertip arthralgia, and cardiac involvement. In addition, the levels of glutamine transaminase (GGT), alanine aminotransferase (ALT), creatine kinase (CK), creatine kinase isoenzyme‐MB (CK‐MB), lactate dehydrogenase (LD), immunoglobulin G (IgG), immunoglobulin A (IgA), C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), and the positive rate of anti‐Scl70 antibody in the high ferritin SSc group were significantly higher (each p < 0.05). SF was positively correlated with GGT, ALT, CK, CK‐MB, LD, IgA, CRP, and ESR (each p < 0.05). Multiple linear regression analysis showed that cardiac involvement, ALT, and ESR were independent influencing factors of SF in SSc.Conclusion: Our study shows that the level of SF in patients with SSc is increased, and the elevated SF is related to abnormal liver function, myocardial involvement, inflammatory status, and production of autoantibodies in SSc. Cardiac involvement, ALT, and ESR are independent factors affecting SF in SSc.
- 9 July 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (8) , e24597
Open AccessClinical significance of serum ferritin in patients with systemic sclerosis
Objective: The purpose of this study was to explore the clinical significance of serum ferritin (SF) in patients with systemic sclerosis (SSc).Methods: The levels of SF were measured in 115 patients with SSc and 117 healthy controls (HCs). Clinical characteristics and laboratory indexes between the high ferritin SSc group and the normal ferritin SSc group were analyzed.Results: The level of SF in SSc patients was significantly higher than that in HCs (319.78 [179, 554.33] ng/ml vs. 99 [49.03, 164.29] ng/ml, p < 0.01). Compared with the normal ferritin SSc group, the high ferritin SSc group was more likely to develop skin diffuse cutaneous SSc, fingertip arthralgia, and cardiac involvement. In addition, the levels of glutamine transaminase (GGT), alanine aminotransferase (ALT), creatine kinase (CK), creatine kinase isoenzyme‐MB (CK‐MB), lactate dehydrogenase (LD), immunoglobulin G (IgG), immunoglobulin A (IgA), C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), and the positive rate of anti‐Scl70 antibody in the high ferritin SSc group were significantly higher (each p < 0.05). SF was positively correlated with GGT, ALT, CK, CK‐MB, LD, IgA, CRP, and ESR (each p < 0.05). Multiple linear regression analysis showed that cardiac involvement, ALT, and ESR were independent influencing factors of SF in SSc.Conclusion: Our study shows that the level of SF in patients with SSc is increased, and the elevated SF is related to abnormal liver function, myocardial involvement, inflammatory status, and production of autoantibodies in SSc. Cardiac involvement, ALT, and ESR are independent factors affecting SF in SSc.